New combo aims to wipe out aggressive breast cancer before surgery

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically or cytologically confirmed newly diagnosed ER-/HER2- breast cancer. ER and PR with Allred score \<3 or \<1% positively stained cells in tumor infiltrating components. HER2 negativity defined as 0 or 1+ by FISH or IHC staining per NCCN guidelines; 2. Clinical stage II or III breast cancer eligible for neoadjuvant chemotherapy (per AJCC 8th edition: at least T2 any N M0, or any T if N+), with treatment goal of complete surgical resection following neoadjuvant therapy; 3. Tumor size ≥2 cm by clinical or imaging assessment per WHO criteria. Patients with histologically confirmed or clinically palpable lymph nodes are eligible regardless of tumor size; 4. Treatment-naïve subjects; 5. Age ≥18 years, both genders eligible; 6. ECOG performance status 0-1; 7. Adequate bone marrow, cardiac, and organ function; 8. Women of childbearing potential must have a negative pregnancy test (serum or urine HCG) within 30 days prior to study enrollment and must practice effective contraception during the study; 9. Ability to comprehend and provide written informed consent. Exclusion Criteria: 1. History of invasive malignancies within 5 years prior to signing the informed consent form, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or carcinoma in situ of the cervix; 2. Subjects who have received chemotherapy, immunotherapy, targeted therapy, or radiotherapy within the past 12 months; 3. Stage IV metastatic breast cancer; 4. Administration of a vaccine within 30 days before the first dose of the study treatment; 5. Subjects with severe systemic diseases; 6. Subjects with active infections (including but not limited to HIV, hepatitis B or C, tuberculosis); 7. Severe cardiovascular diseases, such as: history of myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass grafting within the past 6 months; or congestive heart failure (CHF) of New York Heart Association (NYHA) class II-IV, or history of CHF NYHA class III or IV; 8. Lactating women should discontinue breastfeeding during the study; 9. Subjects with known allergies to the study drug or any of its excipients; 10. Any other condition deemed inappropriate for participation in the study by the investigator. \-